| VERASTEM INC. NEW |
| USA |
| Gesundheit |
| US92337C2035 / A3EHM3 |
| 2VSA (Frankfurt) / VSTM (NASDAQ) |
| FRA:2VSA, ETR:2VSA, 2VSA:GR, NASDAQ:VSTM |
| - |
| https://www.verastem.com/ |
|
Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway. Verastem Oncology’s current portfolio includes marketed and investigat..
>Volltext.. |
| 604.85 Mio. EUR |
| 559.12 Mio. EUR |
| 78.46 Mio. EUR |
| -142.22 Mio. EUR |
| -181.71 Mio. EUR |
| -2.21 EUR |
| 75.6 Mio. EUR |
| 122.24 Mio. EUR |
| -145.4 Mio. EUR |
| 1.75 |
| 4124.6% |
| -25.53% |
| - |
| - |
| - |
| VERASTEM |
| 15.10.26 |
|